<DOC>
	<DOC>NCT00736866</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of acetylcysteine compared to placebo for the contrast-induced nephropathy prevention, between 48 and 96 hours after procedures that use contrast. Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the procedure.</brief_summary>
	<brief_title>The Acetylcysteine for Contrast-Induced Nephropathy Trial</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>At least one of the following criteria: Aged more than 70 yearsold Chronic renal failure (defined as serum creatinine higher than 1.5mg/dL within the last 3 months) Diabetes mellitus Congestive heart failure or ventricular disfunction (left ventricular ejection fraction less than 0.45) Shock or intraaortic balloon pump use Urgency or emergency procedures Pregnant women, breastfeeding or aged below 45 yearsold and with no efficacious contraceptive methods. Patients in dialysis Previous inclusion in this trial Patient refusal to informed consent Pacientes com Infarto Agudo do Miocárdio com supradesnivelamento do segmento ST nos quais não seja possível administrar o protocolo de hidratação pré e pósprocedimento.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>acetylcysteine</keyword>
	<keyword>contrast-induced nephropathy</keyword>
	<keyword>angiography</keyword>
	<keyword>angioplasty with or without Stent</keyword>
</DOC>